<DOC>
	<DOC>NCT01469793</DOC>
	<brief_summary>This multicenter, open-label, dose-escalating study will assess the safety, tolerability, and pharmacokinetics of DMOT4039A in participants with unresectable pancreatic or platinum-resistant ovarian cancer. Cohorts of participants will receive multiple ascending intravenous doses of DMOT4039A.</brief_summary>
	<brief_title>A Study of DMOT4039A in Participants With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 Histologically documented, incurable, locally advanced or metastatic disease for which no standard therapy exists, consisting of one of the following: Unresectable pancreatic ductal adenocarcinoma or platinumresistant ovarian cancer Measureable disease, defined as at least one bidimensionally measurable nonlymph node lesion greater than or equal to (&gt;/=) 1 centimeter (cm) in longaxis diameter on spiral computed tomography (CT) scan or at least one bidimensionally measurable lymph node measuring &gt;/= 1.5 cm in shortaxis diameter on spiral CT scan Adequate hematological, renal and liver function Treatment with antitumor therapy, including chemotherapy, biologic, experimental or hormonal therapy, within 4 weeks prior to Day 1 Known active infection Current Grade &gt;/= 2 toxicity (except for alopecia, anorexia and fatigue) from prior therapy or Grade &gt;/= 2 neuropathy Untreated or active cerebral nervous system metastases Pregnant or breastfeeding women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>